Aclaris Therapeutics (ACRS) Profit After Tax (2017 - 2025)
Historic Profit After Tax for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$14.6 million.
- Aclaris Therapeutics' Profit After Tax fell 9264.43% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.7 million, marking a year-over-year decrease of 28287.75%. This contributed to the annual value of -$132.1 million for FY2024, which is 4925.8% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Profit After Tax is -$14.6 million, which was down 9264.43% from -$15.4 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Profit After Tax registered a high of -$1.5 million during Q4 2023, and its lowest value of -$96.6 million during Q4 2024.
- Its 5-year average for Profit After Tax is -$23.3 million, with a median of -$20.0 million in 2022.
- Its Profit After Tax has fluctuated over the past 5 years, first surged by 9460.47% in 2023, then plummeted by 637565.39% in 2024.
- Over the past 5 years, Aclaris Therapeutics' Profit After Tax (Quarter) stood at -$22.8 million in 2021, then dropped by 21.18% to -$27.6 million in 2022, then soared by 94.6% to -$1.5 million in 2023, then tumbled by 6375.65% to -$96.6 million in 2024, then skyrocketed by 84.86% to -$14.6 million in 2025.
- Its Profit After Tax was -$14.6 million in Q3 2025, compared to -$15.4 million in Q2 2025 and -$15.1 million in Q1 2025.